DECENTRALIZED TRIAL (DCT) TECHNOLOGY INSIGHTS
-
![modern financial management, female investor empowerment, remote participation-GettyImages-2222754770]( "DiMe's Navigator: Why Teams Still Stall On Digital Endpoints")
DiMe's Navigator: Why Teams Still Stall On Digital EndpointsDiMe’s sDHT Adoption Navigator helps clinical teams move from guidance to action, but the real test is whether organizations use it early enough to matter.
-
![API Application Programming Interface connects services, internet data communication-GettyImages-2203607940]( "Digital Endpoints Are Ready. Clinical Development Isn't")
Digital Endpoints Are Ready. Clinical Development Isn'tRegulatory guidance and validation science for digital endpoints are solid. The real barrier is cross-functional execution – and the cost of waiting is compounding.
DCT TECHNOLOGY VIDEOS
This AI-powered digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure.
Optimize flexible electronic patient-reported outcomes that allow participants to switch between site-owned devices, personal hardware, and remote completion.
IQVIA One Home for Sites is a platform that serves as a neutral aggregator, connector, and communicator of the key systems and tasks a clinical research site needs to perform across all the trials it is conducting.
While advances in sensors and device design are improving wearability, successful data collection still hinges on participant adherence. The session highlights why addressing this can’t be an afterthought.
DCT TECHNOLOGY RESOURCES
-
![GettyImages-1164421422 data]( "The Right EDC Solution For Oncology Trials")
Oncology clinical trials can be very complex, as are their data management needs. Understand why selecting the right EDC is crucial for managing them efficiently while providing compassionate care.
-
![your-path-to-decentralized-clinical-trials-0001831902058]( "RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk")
This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.
-
![GettyImages-1404066970 patient]( "Benefits Of Using ePRO In Early Phase Studies")
Discover how harnessing Patient Reported Outcomes electronically in early-phase trials can boost patient centricity, create more cost-effective operations, and help generate better data faster.
-
![How Should Biosimilar Companies Approach Real-World Evidence?]( "Evidence Generation Evolved")
Explore how innovative strategies are cutting clinical trial times in half and accelerating the delivery of life-saving treatments.
-
![GettyImages-1257716223 fda guide]( "The Final DCT Guidance: I'm Not Mad At It")
Explore the FDA's 2024 final guidance on DCTs, including key updates that address previous concerns, affecting healthcare providers, sub-investigators, and sponsors.
-
![GettyImages-1315159023 oncology ps]( "Addressing The Specific Complexities Of Oncology eCOA Clinical Trials")
What are the specific tools and keys to conduct eCOA trials in oncology successfully? This article identifies some of the relevant solutions to tackle oncology protocol complexities.
-
![GettyImages-1322205575 data ps]( "EDC For Mid-Study Changes In Medical Device Clinical Trials")
In this case study, discover how a company was pointed to an electronic data capture (EDC) system that was quick to adapt and easy to scale as the study changed.
